Email this article Prognostic value of pathogenetic therapy-induced changes in NT-proBNP in patients with chronic heart failure
- Authors: Mezhonov EM1, Shalaev SV1
-
Affiliations:
- "ТюмГМА Росздрава"
- Issue: Vol 84, No 9 (2012)
- Pages: 71-75
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31122
- ID: 31122
Cite item
Full Text
Abstract
Aim. To study the prognostic value of therapy-induced changes in plasma NT-proBNP levels in patients with left ventricular (LV) systolic dysfunction. Subjects and methods. The study covered 84 patients aged 23 to 70 years (mean 54±8.1 years) with LV systolic dysfunction (an ejection fraction of <40%). Plasma NT-proBNP levels were determined in all the patients at baseline and 3 months later to evaluate the efficiency of therapy for heart failure (HF). The median follow-up was 18 months. The follow-up recorded the following outcomes (end points): death from decompensated HF and unplanned hospital admissions for progressive HF symptoms. Results. The baseline and therapy high plasma levels of NT-proBNP (more than 3000 pg/ml) were associated with worsening prognosis. The therapy-induced decrease in NT-proBNP levels was associated with more favorable prognosis. Conclusion. Repeat dynamic determination of plasma NT-proBNP levels allows identification of patients at increased risk of poor outcomes for a more intensive observation and more aggressive pathogenetic therapy.
Full Text
##article.viewOnOriginalSite##About the authors
E M Mezhonov
"ТюмГМА Росздрава"
Email: homunculus@aport.ru
S V Shalaev
"ТюмГМА Росздрава"
Email: Shalaev@tokb.ru
References
- Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиол и сердечно-сосудистая хир 2007; 1: 45-51.
- Бугримова М.А., Савина Н.М., Ваниева О.С., Сидоренко Б.А. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология 2006; 1: 51-57.
- Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24 (5): 442-463.
- Jourdain P., Jondeau G., Funck F. et al. Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure. The STARS-BNP Multicenter Study. Am Coll Cardiol 2007; 49: 1733-1739.
- Maisel A., Koon J., Krishnaswamy P. et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-374.
- Troughton R.W., Frampton C., Yandle T. et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
- Yoshimura M., Mizuno Y., Nakamura M. et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002; 12 (9): 716-720.
- Bettencourt P., Azevedo A., Pimenta J. et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-2174.
- Maisel A., Mueller C., Adams K. et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10 (9): 824-839.
- Schou M., Gustafsson F., Kjaer A., Hildebrandt P.R. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007; 28 (2): 177-182.
Supplementary files
